PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?

INTRODUCTION: Programmed death ligand 1 (PD-L1) testing of non-small cell lung cancer (NSCLC) specimens helps select patients most likely to respond to immune checkpoint inhibitors. PD-L1 immunohistochemical testing is approved for formalin-fixed, paraffin-embedded (FFPE) surgical pathology specimen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Soc Cytopathol
Main Authors: Torous, Vanda F., Rangachari, Deepa, Gallant, Benjamin P., Shea, Meghan, Costa, Daniel B., VanderLaan, Paul A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5919255/
https://ncbi.nlm.nih.gov/pubmed/29713584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jasc.2018.02.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados